COVID-19 Impact on Global CD Antigen Cancer Therapy, Market Insights and Forecast to 2026
- BMR3903701
- 114 Pages
- June 2020
- Healthcare
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the CD Antigen Cancer Therapy industry.
Based on our recent survey, we have several different scenarios about the CD Antigen Cancer Therapy YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of CD Antigen Cancer Therapy will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global CD Antigen Cancer Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global CD Antigen Cancer Therapy market in terms of both revenue and volume.
Players, stakeholders, and other participants in the global CD Antigen Cancer Therapy market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Sales and Pricing Analyses
Readers are provided with deeper sales analysis and pricing analysis for the global CD Antigen Cancer Therapy market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.
In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global CD Antigen Cancer Therapy market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global CD Antigen Cancer Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global CD Antigen Cancer Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global CD Antigen Cancer Therapy market.
The following manufacturers are covered in this report:
AryoGen Biopharma
Biocad
Biogen Idec
Celltrion
Genentech
Genmab
GLYCART Biotechnology
Hetero Drugs
mAbxience
MedImmune
Merck
Sandoz
UCB
CD Antigen Cancer Therapy Breakdown Data by Type
Monoclonal Antibodies
Antibody-Drug-Conjugates
Tri-Functional and Bi-Specific T-Cell Engager Antibodies
Other
CD Antigen Cancer Therapy Breakdown Data by Application
Hospitals
Clinics
Other
1.1 CD Antigen Cancer Therapy Product Introduction
1.2 Market Segments
1.3 Key CD Antigen Cancer Therapy Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by Type
1.4.2 Monoclonal Antibodies
1.4.3 Antibody-Drug-Conjugates
1.4.4 Tri-Functional and Bi-Specific T-Cell Engager Antibodies
1.4.5 Other
1.5 Market by Application
1.5.1 Global CD Antigen Cancer Therapy Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Coronavirus Disease 2019 (Covid-19): CD Antigen Cancer Therapy Industry Impact
1.6.1 How the Covid-19 is Affecting the CD Antigen Cancer Therapy Industry
1.6.1.1 CD Antigen Cancer Therapy Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and CD Antigen Cancer Therapy Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for CD Antigen Cancer Therapy Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 Executive Summary
2.1 Global CD Antigen Cancer Therapy Market Size Estimates and Forecasts
2.1.1 Global CD Antigen Cancer Therapy Revenue 2015-2026
2.1.2 Global CD Antigen Cancer Therapy Sales 2015-2026
2.2 CD Antigen Cancer Therapy Market Size by Region: 2020 Versus 2026
2.2.1 Global CD Antigen Cancer Therapy Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global CD Antigen Cancer Therapy Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global CD Antigen Cancer Therapy Competitor Landscape by Players
3.1 CD Antigen Cancer Therapy Sales by Manufacturers
3.1.1 CD Antigen Cancer Therapy Sales by Manufacturers (2015-2020)
3.1.2 CD Antigen Cancer Therapy Sales Market Share by Manufacturers (2015-2020)
3.2 CD Antigen Cancer Therapy Revenue by Manufacturers
3.2.1 CD Antigen Cancer Therapy Revenue by Manufacturers (2015-2020)
3.2.2 CD Antigen Cancer Therapy Revenue Share by Manufacturers (2015-2020)
3.2.3 Global CD Antigen Cancer Therapy Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by CD Antigen Cancer Therapy Revenue in 2019
3.2.5 Global CD Antigen Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 CD Antigen Cancer Therapy Price by Manufacturers
3.4 CD Antigen Cancer Therapy Manufacturing Base Distribution, Product Types
3.4.1 CD Antigen Cancer Therapy Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers CD Antigen Cancer Therapy Product Type
3.4.3 Date of International Manufacturers Enter into CD Antigen Cancer Therapy Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global CD Antigen Cancer Therapy Market Size by Type (2015-2020)
4.1.1 Global CD Antigen Cancer Therapy Sales by Type (2015-2020)
4.1.2 Global CD Antigen Cancer Therapy Revenue by Type (2015-2020)
4.1.3 CD Antigen Cancer Therapy Average Selling Price (ASP) by Type (2015-2026)
4.2 Global CD Antigen Cancer Therapy Market Size Forecast by Type (2021-2026)
4.2.1 Global CD Antigen Cancer Therapy Sales Forecast by Type (2021-2026)
4.2.2 Global CD Antigen Cancer Therapy Revenue Forecast by Type (2021-2026)
4.2.3 CD Antigen Cancer Therapy Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global CD Antigen Cancer Therapy Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Breakdown Data by Application (2015-2026)
5.1 Global CD Antigen Cancer Therapy Market Size by Application (2015-2020)
5.1.1 Global CD Antigen Cancer Therapy Sales by Application (2015-2020)
5.1.2 Global CD Antigen Cancer Therapy Revenue by Application (2015-2020)
5.1.3 CD Antigen Cancer Therapy Price by Application (2015-2020)
5.2 CD Antigen Cancer Therapy Market Size Forecast by Application (2021-2026)
5.2.1 Global CD Antigen Cancer Therapy Sales Forecast by Application (2021-2026)
5.2.2 Global CD Antigen Cancer Therapy Revenue Forecast by Application (2021-2026)
5.2.3 Global CD Antigen Cancer Therapy Price Forecast by Application (2021-2026)
6 North America
6.1 North America CD Antigen Cancer Therapy by Country
6.1.1 North America CD Antigen Cancer Therapy Sales by Country
6.1.2 North America CD Antigen Cancer Therapy Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America CD Antigen Cancer Therapy Market Facts & Figures by Type
6.3 North America CD Antigen Cancer Therapy Market Facts & Figures by Application
7 Europe
7.1 Europe CD Antigen Cancer Therapy by Country
7.1.1 Europe CD Antigen Cancer Therapy Sales by Country
7.1.2 Europe CD Antigen Cancer Therapy Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe CD Antigen Cancer Therapy Market Facts & Figures by Type
7.3 Europe CD Antigen Cancer Therapy Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific CD Antigen Cancer Therapy by Region
8.1.1 Asia Pacific CD Antigen Cancer Therapy Sales by Region
8.1.2 Asia Pacific CD Antigen Cancer Therapy Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific CD Antigen Cancer Therapy Market Facts & Figures by Type
8.3 Asia Pacific CD Antigen Cancer Therapy Market Facts & Figures by Application
9 Latin America
9.1 Latin America CD Antigen Cancer Therapy by Country
9.1.1 Latin America CD Antigen Cancer Therapy Sales by Country
9.1.2 Latin America CD Antigen Cancer Therapy Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America CD Antigen Cancer Therapy Market Facts & Figures by Type
9.3 Central & South America CD Antigen Cancer Therapy Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa CD Antigen Cancer Therapy by Country
10.1.1 Middle East and Africa CD Antigen Cancer Therapy Sales by Country
10.1.2 Middle East and Africa CD Antigen Cancer Therapy Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa CD Antigen Cancer Therapy Market Facts & Figures by Type
10.3 Middle East and Africa CD Antigen Cancer Therapy Market Facts & Figures by Application
11 Company Profiles
11.1 AryoGen Biopharma
11.1.1 AryoGen Biopharma Corporation Information
11.1.2 AryoGen Biopharma Description, Business Overview and Total Revenue
11.1.3 AryoGen Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AryoGen Biopharma CD Antigen Cancer Therapy Products Offered
11.1.5 AryoGen Biopharma Recent Development
11.2 Biocad
11.2.1 Biocad Corporation Information
11.2.2 Biocad Description, Business Overview and Total Revenue
11.2.3 Biocad Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Biocad CD Antigen Cancer Therapy Products Offered
11.2.5 Biocad Recent Development
11.3 Biogen Idec
11.3.1 Biogen Idec Corporation Information
11.3.2 Biogen Idec Description, Business Overview and Total Revenue
11.3.3 Biogen Idec Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Biogen Idec CD Antigen Cancer Therapy Products Offered
11.3.5 Biogen Idec Recent Development
11.4 Celltrion
11.4.1 Celltrion Corporation Information
11.4.2 Celltrion Description, Business Overview and Total Revenue
11.4.3 Celltrion Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Celltrion CD Antigen Cancer Therapy Products Offered
11.4.5 Celltrion Recent Development
11.5 Genentech
11.5.1 Genentech Corporation Information
11.5.2 Genentech Description, Business Overview and Total Revenue
11.5.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Genentech CD Antigen Cancer Therapy Products Offered
11.5.5 Genentech Recent Development
11.6 Genmab
11.6.1 Genmab Corporation Information
11.6.2 Genmab Description, Business Overview and Total Revenue
11.6.3 Genmab Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Genmab CD Antigen Cancer Therapy Products Offered
11.6.5 Genmab Recent Development
11.7 GLYCART Biotechnology
11.7.1 GLYCART Biotechnology Corporation Information
11.7.2 GLYCART Biotechnology Description, Business Overview and Total Revenue
11.7.3 GLYCART Biotechnology Sales, Revenue and Gross Margin (2015-2020)
11.7.4 GLYCART Biotechnology CD Antigen Cancer Therapy Products Offered
11.7.5 GLYCART Biotechnology Recent Development
11.8 Hetero Drugs
11.8.1 Hetero Drugs Corporation Information
11.8.2 Hetero Drugs Description, Business Overview and Total Revenue
11.8.3 Hetero Drugs Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Hetero Drugs CD Antigen Cancer Therapy Products Offered
11.8.5 Hetero Drugs Recent Development
11.9 mAbxience
11.9.1 mAbxience Corporation Information
11.9.2 mAbxience Description, Business Overview and Total Revenue
11.9.3 mAbxience Sales, Revenue and Gross Margin (2015-2020)
11.9.4 mAbxience CD Antigen Cancer Therapy Products Offered
11.9.5 mAbxience Recent Development
11.10 MedImmune
11.10.1 MedImmune Corporation Information
11.10.2 MedImmune Description, Business Overview and Total Revenue
11.10.3 MedImmune Sales, Revenue and Gross Margin (2015-2020)
11.10.4 MedImmune CD Antigen Cancer Therapy Products Offered
11.10.5 MedImmune Recent Development
11.1 AryoGen Biopharma
11.1.1 AryoGen Biopharma Corporation Information
11.1.2 AryoGen Biopharma Description, Business Overview and Total Revenue
11.1.3 AryoGen Biopharma Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AryoGen Biopharma CD Antigen Cancer Therapy Products Offered
11.1.5 AryoGen Biopharma Recent Development
11.12 Sandoz
11.12.1 Sandoz Corporation Information
11.12.2 Sandoz Description, Business Overview and Total Revenue
11.12.3 Sandoz Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Sandoz Products Offered
11.12.5 Sandoz Recent Development
11.13 UCB
11.13.1 UCB Corporation Information
11.13.2 UCB Description, Business Overview and Total Revenue
11.13.3 UCB Sales, Revenue and Gross Margin (2015-2020)
11.13.4 UCB Products Offered
11.13.5 UCB Recent Development
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 CD Antigen Cancer Therapy Market Estimates and Projections by Region
12.1.1 Global CD Antigen Cancer Therapy Sales Forecast by Regions 2021-2026
12.1.2 Global CD Antigen Cancer Therapy Revenue Forecast by Regions 2021-2026
12.2 North America CD Antigen Cancer Therapy Market Size Forecast (2021-2026)
12.2.1 North America: CD Antigen Cancer Therapy Sales Forecast (2021-2026)
12.2.2 North America: CD Antigen Cancer Therapy Revenue Forecast (2021-2026)
12.2.3 North America: CD Antigen Cancer Therapy Market Size Forecast by Country (2021-2026)
12.3 Europe CD Antigen Cancer Therapy Market Size Forecast (2021-2026)
12.3.1 Europe: CD Antigen Cancer Therapy Sales Forecast (2021-2026)
12.3.2 Europe: CD Antigen Cancer Therapy Revenue Forecast (2021-2026)
12.3.3 Europe: CD Antigen Cancer Therapy Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific CD Antigen Cancer Therapy Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: CD Antigen Cancer Therapy Sales Forecast (2021-2026)
12.4.2 Asia Pacific: CD Antigen Cancer Therapy Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: CD Antigen Cancer Therapy Market Size Forecast by Region (2021-2026)
12.5 Latin America CD Antigen Cancer Therapy Market Size Forecast (2021-2026)
12.5.1 Latin America: CD Antigen Cancer Therapy Sales Forecast (2021-2026)
12.5.2 Latin America: CD Antigen Cancer Therapy Revenue Forecast (2021-2026)
12.5.3 Latin America: CD Antigen Cancer Therapy Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa CD Antigen Cancer Therapy Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: CD Antigen Cancer Therapy Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: CD Antigen Cancer Therapy Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: CD Antigen Cancer Therapy Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key CD Antigen Cancer Therapy Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 CD Antigen Cancer Therapy Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
Table 1. CD Antigen Cancer Therapy Market Segments
Table 2. Ranking of Global Top CD Antigen Cancer Therapy Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global CD Antigen Cancer Therapy Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Monoclonal Antibodies
Table 5. Major Manufacturers of Antibody-Drug-Conjugates
Table 6. Major Manufacturers of Tri-Functional and Bi-Specific T-Cell Engager Antibodies
Table 7. Major Manufacturers of Other
Table 8. COVID-19 Impact Global Market: (Four CD Antigen Cancer Therapy Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for CD Antigen Cancer Therapy Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for CD Antigen Cancer Therapy Players to Combat Covid-19 Impact
Table 13. Global CD Antigen Cancer Therapy Market Size Growth Rate by Application 2020-2026 (K Units)
Table 14. Global CD Antigen Cancer Therapy Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 15. Global CD Antigen Cancer Therapy Sales by Regions 2015-2020 (K Units)
Table 16. Global CD Antigen Cancer Therapy Sales Market Share by Regions (2015-2020)
Table 17. Global CD Antigen Cancer Therapy Revenue by Regions 2015-2020 (US$ Million)
Table 18. Global CD Antigen Cancer Therapy Sales by Manufacturers (2015-2020) (K Units)
Table 19. Global CD Antigen Cancer Therapy Sales Share by Manufacturers (2015-2020)
Table 20. Global CD Antigen Cancer Therapy Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 21. Global CD Antigen Cancer Therapy by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in CD Antigen Cancer Therapy as of 2019)
Table 22. CD Antigen Cancer Therapy Revenue by Manufacturers (2015-2020) (US$ Million)
Table 23. CD Antigen Cancer Therapy Revenue Share by Manufacturers (2015-2020)
Table 24. Key Manufacturers CD Antigen Cancer Therapy Price (2015-2020) (USD/Unit)
Table 25. CD Antigen Cancer Therapy Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers CD Antigen Cancer Therapy Product Type
Table 27. Date of International Manufacturers Enter into CD Antigen Cancer Therapy Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)
Table 30. Global CD Antigen Cancer Therapy Sales Share by Type (2015-2020)
Table 31. Global CD Antigen Cancer Therapy Revenue by Type (2015-2020) (US$ Million)
Table 32. Global CD Antigen Cancer Therapy Revenue Share by Type (2015-2020)
Table 33. CD Antigen Cancer Therapy Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 34. Global CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)
Table 35. Global CD Antigen Cancer Therapy Sales Share by Application (2015-2020)
Table 36. North America CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)
Table 37. North America CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)
Table 38. North America CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)
Table 39. North America CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)
Table 40. North America CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)
Table 41. North America CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
Table 42. North America CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)
Table 43. North America CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
Table 44. Europe CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)
Table 45. Europe CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)
Table 46. Europe CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)
Table 47. Europe CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)
Table 48. Europe CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)
Table 49. Europe CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
Table 50. Europe CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)
Table 51. Europe CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
Table 52. Asia Pacific CD Antigen Cancer Therapy Sales by Region (2015-2020) (K Units)
Table 53. Asia Pacific CD Antigen Cancer Therapy Sales Market Share by Region (2015-2020)
Table 54. Asia Pacific CD Antigen Cancer Therapy Revenue by Region (2015-2020) (US$ Million)
Table 55. Asia Pacific CD Antigen Cancer Therapy Revenue Market Share by Region (2015-2020)
Table 56. Asia Pacific CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)
Table 57. Asia Pacific CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
Table 58. Asia Pacific CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)
Table 59. Asia Pacific CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
Table 60. Latin America CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)
Table 61. Latin America CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)
Table 62. Latin Americaa CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)
Table 63. Latin America CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)
Table 64. Latin America CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)
Table 65. Latin America CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
Table 66. Latin America CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)
Table 67. Latin America CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
Table 68. Middle East and Africa CD Antigen Cancer Therapy Sales by Country (2015-2020) (K Units)
Table 69. Middle East and Africa CD Antigen Cancer Therapy Sales Market Share by Country (2015-2020)
Table 70. Middle East and Africa CD Antigen Cancer Therapy Revenue by Country (2015-2020) (US$ Million)
Table 71. Middle East and Africa CD Antigen Cancer Therapy Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa CD Antigen Cancer Therapy Sales by Type (2015-2020) (K Units)
Table 73. Middle East and Africa CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
Table 74. Middle East and Africa CD Antigen Cancer Therapy Sales by Application (2015-2020) (K Units)
Table 75. Middle East and Africa CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
Table 76. AryoGen Biopharma Corporation Information
Table 77. AryoGen Biopharma Description and Major Businesses
Table 78. AryoGen Biopharma CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. AryoGen Biopharma Product
Table 80. AryoGen Biopharma Recent Development
Table 81. Biocad Corporation Information
Table 82. Biocad Description and Major Businesses
Table 83. Biocad CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Biocad Product
Table 85. Biocad Recent Development
Table 86. Biogen Idec Corporation Information
Table 87. Biogen Idec Description and Major Businesses
Table 88. Biogen Idec CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Biogen Idec Product
Table 90. Biogen Idec Recent Development
Table 91. Celltrion Corporation Information
Table 92. Celltrion Description and Major Businesses
Table 93. Celltrion CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Celltrion Product
Table 95. Celltrion Recent Development
Table 96. Genentech Corporation Information
Table 97. Genentech Description and Major Businesses
Table 98. Genentech CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. Genentech Product
Table 100. Genentech Recent Development
Table 101. Genmab Corporation Information
Table 102. Genmab Description and Major Businesses
Table 103. Genmab CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Genmab Product
Table 105. Genmab Recent Development
Table 106. GLYCART Biotechnology Corporation Information
Table 107. GLYCART Biotechnology Description and Major Businesses
Table 108. GLYCART Biotechnology CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. GLYCART Biotechnology Product
Table 110. GLYCART Biotechnology Recent Development
Table 111. Hetero Drugs Corporation Information
Table 112. Hetero Drugs Description and Major Businesses
Table 113. Hetero Drugs CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Hetero Drugs Product
Table 115. Hetero Drugs Recent Development
Table 116. mAbxience Corporation Information
Table 117. mAbxience Description and Major Businesses
Table 118. mAbxience CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. mAbxience Product
Table 120. mAbxience Recent Development
Table 121. MedImmune Corporation Information
Table 122. MedImmune Description and Major Businesses
Table 123. MedImmune CD Antigen Cancer Therapy Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. MedImmune Product
Table 125. MedImmune Recent Development
Table 126. Merck Corporation Information
Table 127. Merck Description and Major Businesses
Table 128. Merck CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. Merck Product
Table 130. Merck Recent Development
Table 131. Sandoz Corporation Information
Table 132. Sandoz Description and Major Businesses
Table 133. Sandoz CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. Sandoz Product
Table 135. Sandoz Recent Development
Table 136. UCB Corporation Information
Table 137. UCB Description and Major Businesses
Table 138. UCB CD Antigen Cancer Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. UCB Product
Table 140. UCB Recent Development
Table 141. Global CD Antigen Cancer Therapy Sales Forecast by Regions (2021-2026) (K Units)
Table 142. Global CD Antigen Cancer Therapy Sales Market Share Forecast by Regions (2021-2026)
Table 143. Global CD Antigen Cancer Therapy Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 144. Global CD Antigen Cancer Therapy Revenue Market Share Forecast by Regions (2021-2026)
Table 145. North America: CD Antigen Cancer Therapy Sales Forecast by Country (2021-2026) (K Units)
Table 146. North America: CD Antigen Cancer Therapy Revenue Forecast by Country (2021-2026) (US$ Million)
Table 147. Europe: CD Antigen Cancer Therapy Sales Forecast by Country (2021-2026) (K Units)
Table 148. Europe: CD Antigen Cancer Therapy Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Asia Pacific: CD Antigen Cancer Therapy Sales Forecast by Region (2021-2026) (K Units)
Table 150. Asia Pacific: CD Antigen Cancer Therapy Revenue Forecast by Region (2021-2026) (US$ Million)
Table 151. Latin America: CD Antigen Cancer Therapy Sales Forecast by Country (2021-2026) (K Units)
Table 152. Latin America: CD Antigen Cancer Therapy Revenue Forecast by Country (2021-2026) (US$ Million)
Table 153. Middle East and Africa: CD Antigen Cancer Therapy Sales Forecast by Country (2021-2026) (K Units)
Table 154. Middle East and Africa: CD Antigen Cancer Therapy Revenue Forecast by Country (2021-2026) (US$ Million)
Table 155. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 156. Key Challenges
Table 157. Market Risks
Table 158. Main Points Interviewed from Key CD Antigen Cancer Therapy Players
Table 159. CD Antigen Cancer Therapy Customers List
Table 160. CD Antigen Cancer Therapy Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. CD Antigen Cancer Therapy Product Picture
Figure 2. Global CD Antigen Cancer Therapy Sales Market Share by Type in 2020 & 2026
Figure 3. Monoclonal Antibodies Product Picture
Figure 4. Antibody-Drug-Conjugates Product Picture
Figure 5. Tri-Functional and Bi-Specific T-Cell Engager Antibodies Product Picture
Figure 6. Other Product Picture
Figure 7. Global CD Antigen Cancer Therapy Sales Market Share by Application in 2020 & 2026
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Other
Figure 11. CD Antigen Cancer Therapy Report Years Considered
Figure 12. Global CD Antigen Cancer Therapy Market Size 2015-2026 (US$ Million)
Figure 13. Global CD Antigen Cancer Therapy Sales 2015-2026 (K Units)
Figure 14. Global CD Antigen Cancer Therapy Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global CD Antigen Cancer Therapy Sales Market Share by Region (2015-2020)
Figure 16. Global CD Antigen Cancer Therapy Sales Market Share by Region in 2019
Figure 17. Global CD Antigen Cancer Therapy Revenue Market Share by Region (2015-2020)
Figure 18. Global CD Antigen Cancer Therapy Revenue Market Share by Region in 2019
Figure 19. Global CD Antigen Cancer Therapy Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by CD Antigen Cancer Therapy Revenue in 2019
Figure 21. CD Antigen Cancer Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global CD Antigen Cancer Therapy Sales Market Share by Type (2015-2020)
Figure 23. Global CD Antigen Cancer Therapy Sales Market Share by Type in 2019
Figure 24. Global CD Antigen Cancer Therapy Revenue Market Share by Type (2015-2020)
Figure 25. Global CD Antigen Cancer Therapy Revenue Market Share by Type in 2019
Figure 26. Global CD Antigen Cancer Therapy Market Share by Price Range (2015-2020)
Figure 27. Global CD Antigen Cancer Therapy Sales Market Share by Application (2015-2020)
Figure 28. Global CD Antigen Cancer Therapy Sales Market Share by Application in 2019
Figure 29. Global CD Antigen Cancer Therapy Revenue Market Share by Application (2015-2020)
Figure 30. Global CD Antigen Cancer Therapy Revenue Market Share by Application in 2019
Figure 31. North America CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America CD Antigen Cancer Therapy Sales Market Share by Country in 2019
Figure 34. North America CD Antigen Cancer Therapy Revenue Market Share by Country in 2019
Figure 35. U.S. CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America CD Antigen Cancer Therapy Market Share by Type in 2019
Figure 40. North America CD Antigen Cancer Therapy Market Share by Application in 2019
Figure 41. Europe CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe CD Antigen Cancer Therapy Sales Market Share by Country in 2019
Figure 44. Europe CD Antigen Cancer Therapy Revenue Market Share by Country in 2019
Figure 45. Germany CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 48. France CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe CD Antigen Cancer Therapy Market Share by Type in 2019
Figure 56. Europe CD Antigen Cancer Therapy Market Share by Application in 2019
Figure 57. Asia Pacific CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific CD Antigen Cancer Therapy Sales Market Share by Region in 2019
Figure 60. Asia Pacific CD Antigen Cancer Therapy Revenue Market Share by Region in 2019
Figure 61. China CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 62. China CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 68. India CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific CD Antigen Cancer Therapy Market Share by Type in 2019
Figure 84. Asia Pacific CD Antigen Cancer Therapy Market Share by Application in 2019
Figure 85. Latin America CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America CD Antigen Cancer Therapy Sales Market Share by Country in 2019
Figure 88. Latin America CD Antigen Cancer Therapy Revenue Market Share by Country in 2019
Figure 89. Mexico CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America CD Antigen Cancer Therapy Market Share by Type in 2019
Figure 96. Latin America CD Antigen Cancer Therapy Market Share by Application in 2019
Figure 97. Middle East and Africa CD Antigen Cancer Therapy Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa CD Antigen Cancer Therapy Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa CD Antigen Cancer Therapy Sales Market Share by Country in 2019
Figure 100. Middle East and Africa CD Antigen Cancer Therapy Revenue Market Share by Country in 2019
Figure 101. Turkey CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E CD Antigen Cancer Therapy Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E CD Antigen Cancer Therapy Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa CD Antigen Cancer Therapy Market Share by Type in 2019
Figure 108. Middle East and Africa CD Antigen Cancer Therapy Market Share by Application in 2019
Figure 109. AryoGen Biopharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 110. Biocad Total Revenue (US$ Million): 2019 Compared with 2018
Figure 111. Biogen Idec Total Revenue (US$ Million): 2019 Compared with 2018
Figure 112. Celltrion Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Genentech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Genmab Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. GLYCART Biotechnology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. mAbxience Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. MedImmune Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Sandoz Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. UCB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 122. North America CD Antigen Cancer Therapy Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 123. North America CD Antigen Cancer Therapy Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Europe CD Antigen Cancer Therapy Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 125. Europe CD Antigen Cancer Therapy Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Asia Pacific CD Antigen Cancer Therapy Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 127. Asia Pacific CD Antigen Cancer Therapy Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Latin America CD Antigen Cancer Therapy Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 129. Latin America CD Antigen Cancer Therapy Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 130. Middle East and Africa CD Antigen Cancer Therapy Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 131. Middle East and Africa CD Antigen Cancer Therapy Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 132. Porter's Five Forces Analysis
Figure 133. Channels of Distribution
Figure 134. Distributors Profiles
Figure 135. Bottom-up and Top-down Approaches for This Report
Figure 136. Data Triangulation
Figure 137. Key Executives Interviewed
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
